期刊文献+

整合素阻断剂类药物的研究与开发进展 被引量:3

The progress of research and development of integrin inhibitors
下载PDF
导出
摘要 整合素与多种疾病密切相关,是非常有前景的药物靶点。本文通过阐述FDA批准上市的整合素阻断剂类药物和正处于临床研究阶段的整合素阻断剂药物,这些药物在抗肿瘤、抗血栓、抗类风湿性关节炎、抗HIV感染等领域的应用,以及我国的整合素阻断剂类药物的研究现状,综述了整合素阻断剂类药物的研究和开发进展。 Integrins are closely related to a variety of diseases, and have been confirmed to be promising drug targets. This paper summarizes integrin antagonists that have been approved by FDA and are still in clinical studies, shows their applications in the fields of anti-thrombus, anti-tumor, anti-rheumatoid arthritis, and anti-HIV infection, and al- so summarizes current research status of integrin antagonists in our country. In this way the research and development of integrin antagonists in new drug discovery are reviewed.
出处 《中国当代医药》 2013年第17期29-32,35,共5页 China Modern Medicine
基金 国家863计划"多肽分子药靶发现与药物设计技术"(2012AA020304) 国家重大专项"一类生物新药抗肿瘤多肽AP25的研究与开发"(2012ZX09103301-004) 中央高校科研专项资金(JKZ2011012) 江苏省高校"青蓝工程"中青年学术带头人(苏教师[2010]27号)
关键词 整合素阻断剂 抗血栓 抗肿瘤 抗类风湿 抗HIV感染 Integrin inhibitors Anti-thrombus Anti-tumor Anti-rheumatoid arthritis Anti-HIV infection
  • 相关文献

参考文献22

  • 1Barczyk M,Carracedo S,Gullberg D. Integrins[J]. Cell Tissue Res, 2010,339(1 ) :269-280.
  • 2Goodman SL,Picard M. Integrins as therapeutic targets[J]. Ce11,2012, 33(7) :405-412.
  • 3Simoons ML. Effect of glycoprotein I1 b/m a receptor blocker abcix- imab on outcome in patients with acute coronary syndromes without early coronary revascularisation :the GUSTO IV-ACS randomised trial[J]. Lancet, 2001,357 (9272) : 1915-1924.
  • 4Herrmann HC,Moliterno DJ,Ohman EM,et al. Facilitation of early pereutaneous coronary intervention after reteplase with or without ab- eiximab in acute myocardial infarction:results from the SPEED (GUSTO-4 Pilot) Trial[J]. J Am Coil Cardiol,2000,36(5) : 1489-1496.
  • 5Jagroop IA,Mikhailidis DP. The effect of tirofiban on fibrinogen/ago- nist-induced platelet shape change and aggregation[J]. Clin Appl Thromb Hemost, 2008,14 (3) : 295-302.
  • 6Albuquerque A. Comparison of two platelet glycoprotein IIb/IIIa in- hibitors,tirofiban and abeiximab,for the prevention of ischemic events with pereutaneous coronary revascularization[J]. Rev Port Car- dial, 2001,20 ( 9 ) : 927 -928.
  • 7Gurbel P.A.,Bliden K.P.,Zaman K.A.,张迎捷.氯吡格雷加依替巴肽抑制血小板反应性:氯吡格雷加依替巴肽抑制血小板反应性(CLEARPlatelets)研究结果[J].世界核心医学期刊文摘(心脏病学分册),2005,0(9):39-40. 被引量:28
  • 8Robert A. Inhibition of platelet glycoprotein 11 b/llla with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial In- vestigators. Platelet Glycoprotein I] b/Ina in Unstable Angina:Recep- tor Suppression Using Integrilin Therapy[J]. N Engl J Med, 1998,339 (7) :436-443.
  • 9Rudick R,Polman C,Clifford D. et al. Natalizumab:bench to bedside and beyond[J]. JAMA Neurol, 2013,70(2) : 172-182.
  • 10Cox D,Brennan M,Moran N. Integrins as therapeutic targets:lessons and opportunities[J]. Nat Rev Drug Discov, 2010,9 (10) : 804-820.

共引文献27

同被引文献48

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部